MedTrace Logo

Bioequivalence Study of Anastrozole 1 mg Tablet

NCT01105299 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2010-04-16

No results posted yet for this study

Summary

The purpose of this study is to characterize and compare the bioequivalence of CJ anastrozole \[CJ Cheiljedang corp., Seoul, Korea\] with Arimidex® \[AstraZeneca, Wilmington, DE, USA\].

Conditions

  • Healthy

Interventions

DRUG

CJ anastrozole 1 mg tablet

Sponsors & Collaborators

  • HK inno.N Corporation

    collaborator INDUSTRY

  • Asan Medical Center

    lead OTHER

Principal Investigators

  • Hyeong-Seok Lim, MD · Asan Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2008-08-31
Completion
2008-08-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01105299 on ClinicalTrials.gov